Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15):4429–4434

Article  PubMed  Google Scholar 

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9(1):29–33

Article  PubMed  Google Scholar 

Javle M, Curtin NJ (2011) The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Therapeutic Adv Med Oncol 3(6):257–267

Article  CAS  Google Scholar 

Juarez-Salinas H, Sims JL, Jacobson MK (1979) Poly(ADP-ribose) levels in carcinogen-treated cells. Nature 282(5740):740–741

Article  CAS  PubMed  Google Scholar 

Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for metastatic breast cancer in patients with a germline <i>BRCA</i> mutation. N Engl J Med 377(6):523–533

Article  CAS  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H et al (2018) Talazoparib in patients with advanced breast cancer and a germline <i>BRCA</i> mutation. N Engl J Med 379(8):753–763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10(3):143–153

Article  CAS  PubMed  Google Scholar 

Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70

Article  CAS  Google Scholar 

Kumar A, Fernandez-Capetillo O, Carrera AC (2010) Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A 107(16):7491–7496

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toulany M, Lee KJ, Fattah KR, Lin YF, Fehrenbacher B, Schaller M et al (2012) Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Res 10(7):945–957

Article  CAS  PubMed  Google Scholar 

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A et al (2012) PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11):1036–1047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J et al (2012) Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2(11):1048–1063

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D et al (2016) Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell 164(3):433–446

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S et al (2017) Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol 28(3):512–518

Article  CAS  PubMed  Google Scholar 

Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI et al (2019) Olaparib and & #x3b1;-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 20(4):570–580

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16(2):110–120

Article  CAS  PubMed  Google Scholar 

Tung NM, Robson ME, Nanda R, Li T, Vinayak S, Shah PD et al (2024) TBCRC 048 (olaparib expanded) expansion cohorts: phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2. J Clin Oncol 42(16):1021

Article  Google Scholar 

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC et al (2016) Homologous recombination deficiency (hrd) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22(15):3764–3773

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von Minckwitz GTK, Untch M et al (2015) Prediction of pathological complete response (pCR) by homologous recombination deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: results from GeparSixto. Annual meeting of the American Society of Clinical Oncology. J Clin Oncol. https://doi.org/10.1200/jco.2015.33.15_suppl.1004

Article  Google Scholar 

Connolly R, Elkin E, Timms K, Goetz M, Boughey J, Zhang Z, Walsh B, Carpenter J, Storniolo A, Watkins S, Gabrielson E (2016) Abstract P3–07-13: homologous recombination deficiency (HRD) as a predictive biomarker of response to preoperative systemic therapy (PST) in TBCRC008 comprising a platinum in HER2-negative primary operable breast cancer. Cancer Res 76(4_ Supplement):P3-07

Google Scholar 

How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH (2021) Modification of homologous recombination deficiency score threshold and association with long-term survival in epithelial ovarian cancer. Cancers 13(5):946

Article  CAS  PubMed  PubMed Central  Google Scholar 

Telli ML, Metzger O, Timms K, Evans B, Vogel D, Wei H et al (2018) Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. J Clin Oncol 36(15_Suppl):519

Article  Google Scholar 

Layman R, Wesolowski R, Han H, Specht JM, Stringer-Reasor EM, Dees EC, Kabos P, Mayer IA, Vaishampayan U, Lu J, Gogineni K (2022) Abstract PD13-02: phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer. Cancer Res 82(4_Supplement):PD13–PD22

Article  Google Scholar 

Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer. N Engl J Med 366(6):520–529

Article  CAS  PubMed  Google Scholar 

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A et al (2018) Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol 36(16):1556–1563

Article  CAS  PubMed  PubMed Central  Google Scholar 

Esposito A, Viale G, Curigliano G (2019) Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer: a review. JAMA Oncol 5(9):1347–1354

Article  PubMed  Google Scholar 

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo Hope S et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929–1940

Article  PubMed  Google Scholar 

Lee C-Y, Cheng W-F, Lin P-H, Chen Y-L, Huang S-H, Lei K-H et al (2023) An activity-based functional test for identifying homologous recombination deficiencies across cancer types in real time. Cell Rep Med 4(11):101247

Article  CAS  PubMed  PubMed Central  Google Scholar 

Slootbeek PH, Kloots IS, van Oort IM, Kroeze LI, Schalken JA, Bloemendal HJ, Mehra N (2023) Cross-resistance between platinum-based chemotherapy and PARP inhibitors in castration-resistant prostate cancer. Cancers 15(10):2814

Article  CAS  PubMed  PubMed Central  Google Scholar 

McMullen M, Karakasis K, Madariaga A, Oza AM (2020) Overcoming platinum and PARP-inhibitor resistance in ovarian cancer. Cancers 12(6):1607

Article  CAS